James Adams
Chief Technical Officer Tr1x therapeutics
Seminars
Wednesday 28th October 2026
Reducing Safety Risk & Improving Consistency in Next Generation Allogeneic Treg Manufacturing
11:45 am
- Enabling mid process purification to achieve best-in-class drug product purity
- Reducing graft versus host disease risk through tighter process control
- Designing raw material and supply strategies with late-stage trials and commercial scale in mind
